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Background: Hepatoblastoma (HB) is the most common pediatric liver malignancy.
Despite advances in chemotherapeutic regimens and surgical techniques, the survival
of patients with advanced HB remains poor, underscoring the need for new therapeutic
approaches. Chloroquine (CQ), a drug used to treat malaria and rheumatologic diseases,
has been shown to inhibit the growth and survival of various cancer types. We examined
the antineoplastic activity of CQ in cell models of aggressive HB.
Methods: Seven human HB cell models, all derived from chemoresistant tumors, were
cultured as spheroids in the presence of relevant concentrations of CQ. Morphology,
viability, and induction of apoptosis were assessed after 48 and 96 h of CQ treatment.
Metabolomic analysis and RT-qPCR based Death Pathway Finder array were used to
elucidate the molecular mechanisms underlying the CQ effect in a 2-dimensional cell
culture format. Quantitative western blotting was performed to validate findings at the
protein level.
Results: CQ had a significant dose and time dependent effect on HB cell viability both
in spheroids and in 2-dimensional cell cultures. Following CQ treatment HB spheroids
exhibited increased caspase 3/7 activity indicating the induction of apoptotic cell death.
Metabolomic profiling demonstrated significant decreases in the concentrations of NAD+
and aspartate in CQ treated cells. In further investigations, oxidation of NAD+ decreased
as consequence of CQ treatment and NAD+/NADH balance shifted toward NADH.
Aspartate supplementation rescued cells from CQ induced cell death. Additionally,
downregulated expression of PARP1 and PARP2 was observed.
Conclusions: CQ treatment inhibits cell survival in cell models of aggressive HB,
presumably by perturbing NAD+ levels, impairing aspartate bioavailability, and inhibiting
PARP expression. CQ thus holds potential as a new agent in the management of HB.
Keywords: liver cancer, hepatoblastoma, pediatric oncology, poly(ADP)-ribose polymerase, metabolomics,
aspartate, NAD+
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INTRODUCTION
Hepatoblastoma (HB) is a malignant liver neoplasm that usually
occurs in children younger than 4-years (1). It is the most
common primary hepatic malignancy in the pediatric population
with an annual incidence of 1.2–1.5/1,000,000 (2). Risk factors
for HB include low birth weight, pre-maturity, and certain
congenital disorders such as Beckwith-Wiedemann syndrome
and familial adenomatous polyposis (FAP) (3–5). Complete
tumor resection is paramount for optimal outcome, but majority
of HBs are not surgically treatable at the time of diagnosis (6–8).
Platinum-derivatives, cisplatin, and carboplatin, combined with
doxorubicin form the backbone of neoadjuvant and adjuvant
chemotherapy in HB treatment (9). Nonetheless, severe adverse
effects limit the use of these agents, and chemoresistance is a
hallmark of aggressive HB (10–12). Thus, new and less toxic
therapeutic modalities would be desirable to further improve the
results of HB management.
Chloroquine (CQ), a drug discovered in 1934, has been
used broadly in the treatment of malaria, rheumatoid arthritis,
and systemic lupus erythematosus (13–16). CQ also has
documented antineoplastic activity in various solid cancer
types including hepatocellular carcinoma, non-small cell lung
cancer, glioblastoma multiforme, bladder cancer, pancreatic
adenocarcinoma, and colon cancer (17–23). In addition to
its efficacy as monotherapy, CQ has shown potential to
sensitize cancer cells to conventional therapy after primary
treatment has failed (24–28). Currently, there are 21 clinical
trials evaluating efficacy and safety of CQ in oncology practice
(Supplementary Table 1).
Multiple mechanisms underlying the tumor suppressive
activity of CQ have been described. Autophagy is a process
linked to metastasis and activation of chemoresistance in a
context of aggressive cancer, and its inhibition is a widely
recognized mechanism of CQ action (29–32). In vitro studies
have shown that the transforming growth factor beta (TGF-
β), hedgehog, and p53 signaling pathways are affected by
CQ treatment (33–37). Other biological processes impacted by
CQ administration include G2/M cell cycle arrest, increased
apoptosis, altered inflammatory responses, and tumor vessel
normalization (38–42).
Previous studies have shown that autophagy promotes
survival of immortalized HB cells and tumor growth in vivo,
suggesting that therapeutic interventions disturbing autophagic
fluxmay hold potential in HBmanagement (43, 44). In this study,
we demonstrate the efficacy of CQ in 3-dimensional (3D) cell
Abbreviations: ABL1, ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase;
ASP, Aspartate; B2M, Beta-2-Microglobulin; BECN1, Beclin-1; CD40, CD40
Molecule; CD40LG, CD40 Ligand; CQ, Chloroquine; CTSS, Cathepsin S;
DPYSL4, Dihydropyrimidinase Like 4; ESR1, Estrogen Receptor 1; ETC, Electron
transport chain; FAP, Familial adenomatous polyposis; FOXI1, Forkhead Box
I1; GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; HB, Hepatoblastoma;
HPRT1, Hypoxanthine Phosphoribosyltransferase 1; IFNG, Interferon gamma;
IGF1, Insulin Like Growth Factor 1; NAD+, Nicotinamide adenine dinucleotide;
NADH, Nicotinamide adenine dinucleotide hydrogen; PARP1, Poly(ADP)-ribose
polymerase 1; PARP2, Poly(ADP)-ribose polymerase 2; PARPi, Poly(ADP)-ribose
polymerase inhibitor; SQSTM1, Sequestosome 1; TNF, Tumor necrosis factor;
TP53, Tumor Protein P53; TXNL4B, Thioredoxin Like 4B.
models of HB established from patients whose response to the
first line treatments was suboptimal. Further, we shed new light
on the molecular mechanisms of CQ action in HB cells.
MATERIALS AND METHODS
Cell Cultures and Treatments
Immortalized human HB cell line HUH6 was purchased from
Japanese Collection of Research Bioresources Cell Bank (Osaka,
Japan) and maintained as described earlier (45). Recently
established human HB cell lines HB-284, HB-282, HB-303, HB-
243, HB-295, and HB-279 were obtained through collaboration
with XenTech (Evry, France) and cultured in Advanced
DMEM/F12 (Gibco,Waltham,MA, USA) supplemented with 8%
fetal bovine serum, 2µM L-glutamine, 100 units/ml penicillin,
100µg/ml streptomycin sulfate, and 20µM rock kinase inhibitor
Y-27632 (SelleckChem, Houston, TX, USA). Cultures were
maintained at 37◦C in a humified incubator containing 5% CO2.
Cells were treated with CQ diphosphate (#ab142116; Abcam,
Cambridge,MA, USA) dissolved in sterile water as a 10mM stock
solution. Further dilutions were prepared in adequate cell culture
medium. Cell culture medium without CQ served as a control
treatment. For all the experiments fresh culture medium with or
without CQ was replaced daily.
3D Spheroid Cultures
Cells were seeded at density of 3,000 cells/well to low attachment
CellCarrier spheroid ULA 96-well-plates (PerkinElmer,
Waltham, MA, USA). After 72 h incubation, spheroids were
established and treatment with CQ or control medium was
initiated. Images were captured at treatment timepoints of 0,
48, and 96 h with Eclipse TS100 microscope supplemented with
DS-Fi1 digital imaging system (Nikon, Tokyo, Japan).
3D Viability Measurements
Viability of spheroids was assessed with ATPliteTM 3D
monitoring system (PerkinElmer) as described in the
manufacturer’s instructions at treatment timepoints of 48
and 96 h. Luminescence was measured with EnSpire Multimode
Plate Reader (PerkinElmer).
Apoptosis Assay
Caspase 3/7 Glo assay (Promega, Madison, WI, USA) was
used to measure apoptosis in 3D cultures as instructed.
Luminescence was recorded with EnSpire Multimode Plate
Reader (PerkinElmer).
Clonogenic Cell Survival Assay
HUH6, HB-284, and HB-243 cells were seeded at low density in
12-well-plates and cultured for 4 or 14 days after attachment in
absence of CQ or with CQ in concentrations 1, 5, or 10µM. Cells
were fixed with 4% paraformaldehyde, permeabilized with 100%
methanol, and subsequently stained with crystal violet. Images
were captured with Bio-Rad ChemiDoc XRS+ Imaging System
(Bio-Rad, Hercules, CA, USA). Colony number was determined
with ColonyArea Plugin in ImageJ Software (46).
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Metabolomic Profiling
HUH6 cells were treated with control medium or 5µM CQ for
96 h. Next, 1.5 × 106 cells/sample were collected, and cell pellets
were snap-frozen in liquid nitrogen for analysis. Acquity UPLC-
MS/MS system and XEVO TQ-S Triple Quadrupole LC/MS
(Waters Corporation, Milford, MA, USA) were used to analyze
the samples. Normalized concentrations of 100 metabolites were
analyzed with web-based software MetaboAnalyst 4.0 (http://
www.metaboanalyst.ca) (47). Detailed information of sample
processing, reagents, and full protocol are given elsewhere (48).
NAD/NADH Assay
NAD/NADH ratio was measured with NAD/NADH assay kit
purchased from Abcam. Briefly, HUH6 cells were cultured
with or without 5µM CQ for 96 h. Cells were lysed and
processed following manufacturer’s instructions as described
(49). The reaction was allowed to develop for 1.5 h, and
then absorbance was measured at 450 nm with Multiskan
FC microplate reader (Thermo Fisher Scientific, Vantaa,
Finland). NAD/NADH ratio was calculated using normalized
concentrations by equation ([NADtotal—NADH])/[NADH].
Aspartate Rescue Experiment
Cells were treated with 5µM CQ or 5µM CQ supplemented
with 10mM L-aspartic acid (Sigma Aldrich, St. Louis, MO,
USA) for 96 h. The impact of 10mM L-aspartic acid alone
on growth was also monitored. Cell viability was assessed by
ATPLite Luminescence assay system using Enspire Multimode
Plate Reader (both from PerkinElmer).
RNA Extraction and RT-qPCR
Total RNAwas extracted fromHUH6 cells treated with 5µMCQ
or control media for 96 h utilizing RNAeasy Mini Kit (QIAGEN,
Valencia, CA, USA) as instructed. Reverse transcription was
performed with Reverse transcriptase Core kit (Eurogentec,
Seraing, Belgium). RT² Profiler Cell Death Pathway Finder
qPCR array (QIAGEN) was performed as described in the
manufacturer’s instructions. Geometric mean of B2M, HPRT1,
and GAPDH expression served as a reference.
Protein Extraction and Western Blotting
Proteins were extracted utilizing NucleoSpin RNA/Protein
extraction kit (Macherey-Nagel, Düren, Germany). Ten
micrograms of protein was separated by electrophoresis using
Mini-Protean TGX Stain-Free Gels (Bio-Rad). Proteins were
transferred onto polyvinyl fluoride membrane and non-specific
binding was blocked with 5% non-fat milk in 0.1% Tris-
buffered Tween saline buffer. Membranes were incubated
with following primary antibodies at +4◦C for overnight:
anti-human PARP1 rabbit IgG in dilution 1:1,500 (#9532; Cell
Signaling Technology, Danvers, MA, USA) and anti-human
PARP2 rabbit IgG in dilution 1:1,000 (#NBP2-47337; Novus
Biologicals, Littleton, CO, USA). Next, goat anti-rabbit IgG
secondary antibody (#111-035-144 in dilution 1:10,000; Jackson
ImmunoResearch, West Grove, PA, USA) incubation was
performed at room temperature for 1 h. Protein bands were
detected utilizing Enhanced Chemiluminescence detection
kit (Amersham ECL reagent; GE Healthcare, Barrington,
IL) and analyzed with Image Lab Software 6.0 (Bio-rad).
Band intensity was normalized to total protein amount in
each lane.
TABLE 1 | Clinical information of HB patients.
Sample ID HB-303 HB-243 HB-279 HB-282 HB-284 HB-295
Age (months) 69 52 79 12 83 26
Type of sample Primary Intrahepatic relapse Primary Primary Peritoneal
metastasis
at relapse
Primary
R, resection;
LT, liver transplant
R LT LT R R R
Sex F M M M M F
Vascular invasion Y/N N Y Y N n/a Y
S, solitary; M, multiple nodules M M M S n/a M
Metastasis Y/N N N N N n/a Y
Main histological component Fetal Embryonal Embryonal +
Macrotrabecular
Embryonal Embryonal Fetal
PRETEXT II n/a IV II n/a II
Chemotherapy protocol Cisplatin 4 cycles Carboplatin + Etoposide SIOPEL-4 SIOPEL-3 + SIOPEL-6 Etoposide
+ Cisplatin
SIOPEL-4
AFP serum at diagnosis (ng/mL) 158,645 6,000 1,000,000 1,286,000 2,162 585,350
AFP serum post-chemoth.
(ng/mL)
26,000 5,000 30,000 1,000,000 1,089 1,400
PRETEXT, Pre-treatment extent of disease, radiological staging system for primary pediatric liver malignancies. AFP, alpha-fetoprotein. n/a, information is not available. Information
adapted from (50).
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FIGURE 1 | Morphology, viability, and caspase 3/7 activation of HB spheroids treated with CQ. Morphology of HUH6 (A), HB-284 (B), and HB-243 (C) derived
spheroids treated with control medium (0µM) or CQ at concentrations of 1, 5, and 10µM (left panel). Relative ATP concentration (middle panel) and relative caspase
3/7 activation (right panel) in HUH6 (A), HB-284 (B), HB-243 (C) derived spheroids after 48 and 96 h CQ treatment. CQ concentrations; 1, 5, and 10µM. *P < 0.05.
**P < 0.01. Statistical significance was assessed with one-way ANOVA. Bar plots are presented as relative values of mean ± RSD (N = 3). Characteristics of
proliferating, quiescent, and necrotic spheroid morphology (D). Pictures were captured at initiation of treatment (0 h) and after 48 h and 96 h of CQ administration.
Magnification 10×, scale bar = 10µm.
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Immunofluorescence Staining
HUH6 cells (200,000/well) were grown with or without 5µM of
CQ for 96 h on 2-well-chamber slides pre-coated with Matrigel
(Corning, Corning, NY, USA). Subsequently, cells were fixed
and permeabilized with ice-cold 100% methanol (5min, room
temperature). Unspecific binding was blocked with UltraVision
FIGURE 2 | HB 2D cell cultures show decrease in viability and clonogenic potential after CQ exposure. Relative number of colonies after 4 and 14 days of CQ
treatment: HUH6 (A), HB-284 (B), and HB-243 (C). Colonies stained with crystal violet after 4 or 14 days CQ administration. CQ; 1, 5, and 10µM. *P < 0.05, **P <
0.01. One-way ANOVA was utilized to measure statistical significance. Bar plots are presented as relative values of mean ± RSD (N = 3).
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Protein Block (Thermo Fisher Scientific). Next, cells were
incubated with primary antibody at room temperature for 1 h
(#9532 human anti-rabbit PARP1 at 1:800 dilution, Cell Signaling
Technologies). Secondary antibody incubation was performed
with goat anti-rabbit IgG (H+L) AlexaFluor 647 (1 h, room
temperature) at 1:500 dilution (A32733, Invitrogen, Carlsbad,
CA, USA). Images were captured with Zeiss Axio Imager M2
(objective: EC Plan Neofluar 40×/0.75 Ph 2 M27) (Carl-Zeiss,
Oberkochen, Germany).
Statistical Analyses
For viability assays, apoptosis measurements, and RNA and
protein quantifications statistical analyses were performed using
JMP Software (JMP Pro; version 14.1.0, SAS Institute Inc.).
All the experiments were carried out at least in triplicate.
Statistical significance was assessed using Student’s t-test or one-
way ANOVA depending the experimental design. ∗P < 0.05
was considered as a statistically significant and ∗∗p < 0.01 as
a statistically highly significant. Metabolomic profiling analyses
were completed using MetaboAnalyst 4.0. software (47).
RESULTS
HB Spheroids Treated With CQ Show
Decreased ATP Availability and Increased
Cell Death
Since traditional 2D cell cultures do not accurately represent
the architecture and interactions of solid tumors, we assayed the
effect of CQ treatment using 3D HB spheroid models. Six of the
cell lines used in this study were established from aggressive HB
tumors (Clinical details in Table 1) thus representing a situation
of an unfavorable treatment outcome for first line therapy (50).
The seventh cell line, HUH6, is a gold standard in HB research.
Spheroids were treated with three different concentrations of
CQ in an acceptable range (51). Spheroid morphology was
monitored after 48 and 96 h of treatment by capturing brightfield
images with inverted phase contrast microscope. CQ treatment
triggered a time and dose-dependent increase in the necrotic
non-viable zone and loss of proliferative edge in all 7 spheroid
models studied (Figures 1A–C, Supplementary Figures 1A–D).
Characteristics of proliferating, quiescent, and necrotic spheroid
morphology are shown in Figure 1D. Next, the viability of
HB spheroids was quantified by ATP measurements. After 48 h
of CQ treatment a statistically significant decrease in viability
was observed in two out of seven models (Figures 1B,C). By
96 h, six out of seven models showed a significant decrease in
viability (Figures 1A–C, Supplementary Figures 1A,B,D). Since
increased apoptotic cell death has been reported following CQ
treatment (40, 52), we next measured activation of caspase 3/7 in
HB cell spheroids. After 48 h, all 7 models showed a significant
increase in apoptosis with 10µM CQ compared to control
(Figures 1A–C, Supplementary Figures 1A–D). An even more
enhanced caspase 3/7 activation was detected in four out of
seven cell models (Figures 1A–C, Supplementary Figure 1A)
after 96 h, and three out of these four proceeded toward apoptotic
cell death at a lower CQ concentration (5 µM).
TABLE 2 | The most altered metabolites after 96 h CQ (5µM) exposure.
Metabolite FC Log2(FC) P-value
NAD+ 0.39903 −1.3254 0.0006958
Myoinositol 0.46644 −1.1003 0.0028352
4-Pyridoxic acid 3.1111 1.6374 0.0049283
Lysine 3.043 1.6055 0.0075209
Aspartate 0.25574 −1.9672 0.0087533
Betaine 0.095446 −3.3892 0.0096113
Arginine 2.5807 1.3677 0.011984
GABA 0.10494 −3.2524 0.027384
Creatine 0.32802 −1.6081 0.027633
Isovalerylcarnitine 0.274 −1.8678 0.027858
ADMA 2.5424 1.3462 0.028598
Carnitine 0.14461 −2.7898 0.029634
Phosphoethanolamine 0.12009 −3.0578 0.032194
Hydroxyproline 0.41124 −1.282 0.040055
Taurine 0.37727 −1.4063 0.04041
cAMP 0.45375 −1.14 0.041231
Cystathionine 0.34233 −1.5465 0.050692
Octanoylcarnitine 0.4 −1.3219 0.052182
Decanoylcarnitine 0.27586 −1.858 0.064599
Hexanoylcarnitine 0.39548 −1.3383 0.066445
CQ Treatment Impairs Viability in HB 2D
Cell Cultures
Due to low cell density, spheroids are not suitable for many
high throughput applications. To circumvent this limitation, we
validated our 3D spheroid findings in HB cells cultured in a 2D
format. Clonogenic potential was measured after short term (4
days) and long term (14 days) CQ administration. A statistically
highly significant decrease in clone formationwas evident already
after 4 days of treatment at concentrations of 5 and 10µM
(Figures 2A–C), and long-term exposure had the same effect on
cell viability (Figures 2A–C).
CQ Treatment Depletes NAD+ and
Aspartate in HUH6 Cells
Inhibition of autophagic flux is one of the known mechanisms
of CQ action, and dysfunction in this process leads to a
shortage of nutrients in cancer cells (53). Metabolomic
profiling of HUH6 cell line treated with 5µM CQ revealed
a statistically significant decrease in 12 metabolites and an
increase in 4 metabolites (Table 2). Metabolite enrichment set
analysis denoted metabolites associated with malate-aspartate
shuttle to be the most prominently altered (Figure 3A).
Pathway analysis implicated alanine, aspartate, and glutamate
metabolism as having the highest impact (Figure 3B). At the
single metabolite level, nicotine adenine dinucleotide (NAD+)
was the most significantly altered with a 60% decrease in
concentration after CQ treatment (Figure 3C). In further
investigation, NAD+/NADH ratio was noted to be 2.9-fold
higher (p < 0.02) in untreated cells compared to CQ treated
cells (Figure 3D). Aspartate, which was highlighted both in
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FIGURE 3 | Metabolomic alterations in HUH6 cells treated with 5µM CQ. Enrichment analysis showing the most abundantly altered metabolite sets (A). Pathway
impact analysis demonstrating the importance of altered metabolites for pathway functionality (B). NAD+ concentrations (C) and NAD+/NADH (D) ratio in CQ treated
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supplementation on CQ treated or untreated HUH6 cell viability (F). Single metabolites values are given as normalized concentration (µmol/million cells). NAD+/NADH
ratio is presented as percentages of normalized total NAD concentrations. Bar plots are presented as relative values of mean ± RSD, (N = 3). ASP; 10mM aspartate.
Metabolite analyses were performed with MetaboAnalyst 4.0. *P < 0.05, **P < 0.01.
metabolite enrichment and pathway analyses, demonstrated 75%
decrease in concentration when comparing CQ treated cells
to control cells (Figure 3E). Closer evaluation demonstrated
that aspartate supplementation was able to prevent cell death
triggered by CQ treatment. Cell viability was 1.7-fold higher
when cells were treated with 5µM of CQ supplemented
with aspartate compared to CQ treatment (Figure 3F).
Aspartate supplementation alone had no effect on cell viability
(Figure 3F). Normalized metabolite concentrations are shown in
Supplementary Table 2.
Death-Associated Gene Expression
Changes in HUH6 Cells Exposed to CQ
RT² Profiler Cell Death Pathway Finder array recognized 16 out
84 genes (Figure 4) to be statistically significantly differentially
expressed in HUH6 cells treated with 5µM CQ for 96 h. Six
of these genes were classified by the manufacturer as pro-
apoptotic genes (Figures 4A–F: CD40LG, CD40, TNF, TP53,
IFNG, and ABL1), five as autophagy related (Figures 4G–K:
ESR1, IGF1, SQSTM1, BECN1, and CTSS), and five as necroptotic
(Figures 4L–P: PARP1, PARP2, FOXI1, TXNL4B, and DPYSL4).
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L
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FIGURE 4 | Significantly altered genes detected by Cell Death Pathway Finder array. Pro-apoptotic genes (A–E), autophagy associated genes (F–K), necrosis genes
(L–P). Black dots represent normalized expression of independent samples, the box represents the interquartile range, and the whiskers represent the first and fourth
quartile. The solid line is median and dashed line shows mean expression of each gene after 96 h of 5µM CQ or control treatment (N = 4).
Normalized gene expression of the whole array panel is shown in
Supplementary Table 2.
CQ Inhibits PARPs in HB Cells
Given that the most significant alteration found by metabolomic
profiling was a drastic decrease in NAD+ concentration and that
poly(ADP)-ribose polymerase (PARP) function is highly NAD+-
dependent (54), we chose PARP1 and PARP2 (Figures 4M,N) for
further analyses. HUH6, HB-284, and HB-243 cells were treated
with 5µM of CQ for 96 h and subsequently quantitative western
blotting analysis was performed. Statistically significant decrease
in PARP1 protein expression was detected in HUH6 and HB-243
cell lines (Figure 5A), over 60 and 30% reduction, respectively.
Furthermore, immunofluorescence staining revealed decreased
nuclear expression of PARP1 after CQ treatment compared to
control cells (Supplementary Figures 2D–F). Similarly, PARP2
expression was observed to be markedly decreased in cells treated
with CQ (Figure 5B).
DISCUSSION
Chemotherapy resistance is the major obstacle limiting HB
patient survival (10). Therefore, novel treatment strategies are
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relative values of mean ± RSD.
needed for patients with advanced and chemoresistant HB. We
found robust antineoplastic activity of CQ monotherapy in HB
tumor spheroid models. Further, our results shed light on the
molecular mechanisms of the CQ. To this end, our findings
describe the CQ administration associated gene expression
alterations in cell death related pathways, especially the inhibition
of PARP1 and PARP2, as well as metabolomic perturbations
leading to failure in NAD+ balance and aspartate availability.
Spheroids mimic 3D architecture of solid tumors and
offer tissue-like environment for cancer drug research (55).
The patient-derived HB models used here recapitulate the
characteristics of advanced and aggressive original HB tumors
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(50). Taken together, our results demonstrate decreased cell
viability and activation of apoptotic cell death as response to
CQ treatment in these HB cell models. Although spheroids
have multiple advantages compared to the traditional
2D cell cultures, they still lack responses produced by
multicellular organ system. Organoids may better represent
the complexity of tumor and neighboring tissues (56),
and in the future, these findings should be confirmed in
HB organoids.
Aspartate depletion induced by CQ treatment was recently
demonstrated in pancreatic cancer cells restricting nucleotide
biosynthesis and subsequently predisposing cells to the
replication stress (57). Additionally, in oxygen deprived
environment, typical for solid tumors, aspartate has been
suggested to be a limiting metabolite for proliferation
(58, 59). In line with these previous observations, the
present findings demonstrate reduced aspartate availability
and simultaneous decrease in cell viability of HB cells
treated with CQ. Moreover, aspartate supplementation
rescued cells from CQ induced cell death suggesting that
aspartate availability may be one the crucial targets of
this treatment.
Aspartate biosynthesis requires electron acceptors, e.g.,
NAD+, and in the presence of oxygen their pools are
maintained by electron transport chain (ETC) reactions (58,
59). ETC is carried out by four complexes (I–IV) and ATP
synthase. Complex I regenerates NAD+ from NADH and
pharmacological inhibition of that reaction is linked with
disturbed NAD+/NADH balance and subsequent reduction
in aspartate synthesis (59). We noted a contemporaneous
drop in aspartate and NAD+ concentrations in HB cells
treated with CQ, implying that limited aspartate availability
may be a consequence of ETC malfunction. In addition,
NAD+/NADH balance shifted toward NADH following CQ
treatment, suggesting that CQ impacts NAD oxidation. Further
investigations are needed to determine whether inhibition of
mitochondrial complex I is a bona fide mechanism of CQ action
in HB cells.
FIGURE 6 | Schematic view of proposed CQ action in HUH6 cells.
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PARPs are multifunctional enzymes involved in epigenetic
modifications, signal transduction, stress sensing, and DNA
repair (60–62). Interestingly, in a context of aggressive
HB, PARP1 was recently shown to be aberrantly activated,
promoting expression of nonfunctional tumor suppressor
proteins (63). Herein, we demonstrated decreases in PARP1
and PARP2 expression in HB cells both at mRNA and protein
level after CQ treatment. Since the catalytic activities of
PARP1 and PARP2 are NAD+ dependent (54), we suggest
that reduced NAD+ pools trigger degradation of PARPs.
Moreover, CQ may downregulate aberrantly expressed tumor
suppressor proteins by PARP inhibition compromising HB
cell survival. The PARP inhibitor (PARPi) talazoparib has been
shown to synergize with CQ in a pediatric chronic myeloid
leukemia mouse model (64). Another PARPi, niraparib,
combined with CQ exhibited increased cytotoxicity in
hepatocellular carcinoma in vitro and in vivo (65). It would
be of interest to study whether a similar synergism exists also in
HB models.
All in all, our results suggest that CQ has potential as an
additional treatment modality for aggressive HB through the
mechanisms summarized in Figure 6. Thus, this pre-clinical
study sets the basis for further investigations in HB and offers
novel potential applications for CQ re-purposing strategies.
CONCLUSIONS
CQ treatment in relevant concentrations decreases viability
of HB spheroids. Further, the spheroids established from
chemoresistant tumors exhibited increased apoptotic activity
after CQ treatment, suggesting that CQ holds potential in
treatment of aggressive HB. Moreover, our study demonstrates
disturbance in NAD+ and aspartate metabolism exposing
cells to impaired DNA repair and histone remodeling
by PARPs.
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